Research / RMR / Fundamental state Inspectable configuration
State dimensions Filing 0001644378-25-000033 General Corporate
Operating cash generation 91th Own-history percentile · N=11
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
50.20% · OPTIONAL · VALID
Revenue growth RAW Current state valid · history insufficient
Evidence method Yoy · gp.fundamentals.revenue
-78.55% · CORE · NOT_ENOUGH_HISTORY
Operating margin 82th Own-history percentile · N=11
Evidence method Level · gp.fundamentals.operating_margin
22.63% · CORE · VALID
SBC intensity 91th Own-history percentile · N=11
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
4.74% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 12 states History building
Sep 30, 2023 0/5 normalized Level 3 Dec 31, 2023 0/6 normalized Level 3 Mar 31, 2024 0/6 normalized Level 3 Jun 30, 2024 0/6 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 4/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 3/4 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 3 Period transition
What moved in the state? Cash Generation Increased
Previous 28.49%
Current 50.20%
Delta 21.71% Growth Increased
Previous -79.10%
Current -78.55%
Delta 0.55% Profitability Increased
Previous 16.61%
Current 22.63%
Delta 6.02% Sbc Intensity Increased
Previous 3.53%
Current 4.74%
Delta 1.21% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.